TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15582348

Group type: EXPERIMENTAL
Intervention: Self-treatment program with additional information on recognizing prodromal signs and doubling inhaled corticosteroids (ICS) during one week
Number of subjects: 29

Group type: COMPARATOR
Intervention: Structured information on asthma, symptoms, and medication
Number of subjects: 29
Study: 11393635

Group type: EXPERIMENTAL
Intervention: Nurse-monitored exercise (ME)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Nurse-coached exercise (CE)
Number of subjects: 45
Study: 9416012

Group type: EXPERIMENTAL
Intervention: Drop-jumps from a height of 0.28 m
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pendulum rebounds
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standing condition
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Drop-jumps
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pendulum exercises
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both exercise regimens
Number of subjects: 8
Study: 11767316

Group type: EXPERIMENTAL
Intervention: Intravenous sufentanil (150 micrograms)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Epidural sufentanil (150 micrograms)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil (150 micrograms)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no sufentanil)
Number of subjects: 60
Study: 3793280

Group type: EXPERIMENTAL
Intervention: Nisoldipine (4-8 micrograms/kg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Metoprolol (10 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combination therapy (Nisoldipine + Metoprolol)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Order of administration (Nisoldipine added to Metoprolol)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dynamic exercise
Number of subjects: 16
Study: 29359848

Group type: EXPERIMENTAL
Intervention: Weight-based treatment (0.3 g glucose/kg body-weight)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fixed dose of 12 g glucose
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fixed dose of 30 g glucose
Number of subjects: 30
Study: 25989706

Group type: EXPERIMENTAL
Intervention: IVB + TRP group
Number of subjects: 38

Group type: COMPARATOR
Intervention: IVB group
Number of subjects: 38
Study: 25141250

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 104

Group type: COMPARATOR
Intervention: Labetalol
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 104
Study: 22321758

Group type: EXPERIMENTAL
Intervention: Home rehabilitation program once a month for 6 months with audiovisual materials
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Home rehabilitation program
Number of subjects: 60
Study: 20478741

Group type: EXPERIMENTAL
Intervention: eszopiclone 3mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: fluoxetine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Insomnia Severity Index (ISI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 17462639

Group type: EXPERIMENTAL
Intervention: GnRH agonist trigger after cotreatment with GnRH antagonist
Number of subjects: 66

Group type: COMPARATOR
Intervention: hCG trigger after dual pituitary suppression with a GnRH agonist
Number of subjects: 66
Study: 15982504

Group type: EXPERIMENTAL
Intervention: Oral vitamin C administration
Number of subjects: 44

Group type: COMPARATOR
Intervention: No additional therapy (Control)
Number of subjects: 44
Study: 11865815

Group type: EXPERIMENTAL
Intervention: TMTX/5-FU/LV (TMTX 110 mg/m2 i.v. followed by LV 200 mg/m2/5-FU 500 mg/m2 plus oral LV rescue)
Number of subjects: 746

Group type: COMPARATOR
Intervention: 5-FU/LV (5-FU 600 mg/m2 in Europe and 500 mg/m2 in USA)
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: TMTX/5-FU/LV
Number of subjects: 746

Group type: COMPARATOR
Intervention: 5-FU/LV
Number of subjects: 746
Study: 11100888

Group type: EXPERIMENTAL
Intervention: Group II lens (Soflens 66)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Group IV lens (Acuvue)
Number of subjects: 22
Study: 8732588

Group type: EXPERIMENTAL
Intervention: Haloperidol treatment
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 173
Study: 1414927

Group type: EXPERIMENTAL
Intervention: Trandolapril 2 mg once daily
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 2861844

Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg twice daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg twice daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Terfenadine and Cimetidine (in combination)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30207844

Group type: EXPERIMENTAL
Intervention: Continuous diffusion of oxygen (CDO) therapy
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 146
Study: 26374194

Group type: EXPERIMENTAL
Intervention: Children's self-identified goals (n=18) using the Perceived Efficacy and Goal-Setting System
Number of subjects: 34

Group type: COMPARATOR
Intervention: Goals identified by parents (n=16) using the Canadian Occupational Performance Measure (COPM)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Comparison of both groups post-intervention
Number of subjects: 34
Study: 24389521

Group type: EXPERIMENTAL
Intervention: Circuit resistance training (CRT) performed three times weekly for 40‐45 min each session with immediate protein supplementation (PS) of whey protein = 36‐37 g before and after exercise
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Circuit resistance training (CRT) performed three times weekly for 40‐45 min each session with delayed protein supplementation (PS) of matched protein dose 24 h postexercise
Number of subjects: 11
Study: 22153143

Group type: EXPERIMENTAL
Intervention: Mindfulness training through yoga, 1 hour a week for 8 weeks, plus 10 minutes of daily homework
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study: 20630302

Group type: EXPERIMENTAL
Intervention: Apical negative pressure (ANP) irrigation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Passive ultrasonic (PUI) activation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Endoactivator (sonic activation)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: F file
Number of subjects: 100

Group type: COMPARATOR
Intervention: Positive pressure irrigation (control group)
Number of subjects: 100
Study: 18652112

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with modern rehabilitation techniques
Number of subjects: 60

Group type: COMPARATOR
Intervention: Rehabilitation treatment only
Number of subjects: 60
Study: 16236699

Group type: EXPERIMENTAL
Intervention: Patient portal
Number of subjects: 606

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 606
Study: 12870876

Group type: EXPERIMENTAL
Intervention: 1 mL Oil of Wintergreen
Number of subjects: 4

Group type: COMPARATOR
Intervention: 6.7 g of Ben Gay 15%
Number of subjects: 4

Group type: COMPARATOR
Intervention: 20 g of Ben Gay 15%
Number of subjects: 4

Group type: COMPARATOR
Intervention: 5 g of Ben Gay 15% cream held in the buccal cavity for 1 minute and then expectorated
Number of subjects: 4
Study: 10554538

Group type: EXPERIMENTAL
Intervention: Sodium selenite i.v. 1 mg bolus/2 x 1 mg infusion 1 day before ERCP
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Metronidazole 0.5 g/ofloxacin 0.2 g before and 6 hours after ERCP
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 60
Study: 8919724

Group type: EXPERIMENTAL
Intervention: Tetracycline (500 mg orally every 6 hours for 3 days)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Co-trimoxazole (160 mg of trimethoprim and 800 mg of sulfamethoxazole orally every 12 hours for 3 days)
Number of subjects: 107
Study: 31910835

Group type: EXPERIMENTAL
Intervention: Familial social capital (family sense of belonging)
Number of subjects: 2068

Group type: EXPERIMENTAL
Intervention: Familial social capital (family autonomy support)
Number of subjects: 2068

Group type: EXPERIMENTAL
Intervention: Familial social capital (family control)
Number of subjects: 2068

Group type: EXPERIMENTAL
Intervention: School social capital (school sense of belonging)
Number of subjects: 2068

Group type: EXPERIMENTAL
Intervention: Socioeconomic status (SES)
Number of subjects: 2068
Study: 31347994

Group type: EXPERIMENTAL
Intervention: Lowest quintile of GWG rate
Number of subjects: 14219

Group type: EXPERIMENTAL
Intervention: Highest quintile of GWG rate
Number of subjects: 14219
Study: 27802927

Group type: EXPERIMENTAL
Intervention: Biolimus-eluting stent with biodegradable polymer (BP-BES)
Number of subjects: 5942

Group type: COMPARATOR
Intervention: Everolimus-eluting stent with durable polymer (DP-EES)
Number of subjects: 5942
Study: 26194374

Group type: EXPERIMENTAL
Intervention: TSU-68 plus docetaxel
Number of subjects: 77

Group type: COMPARATOR
Intervention: Docetaxel alone
Number of subjects: 77
Study: 24399652

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study: 23036875

Group type: EXPERIMENTAL
Intervention: Osteopathic visceral mobilisation of the sigmoid colon
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 15
Study: 19248698

Group type: EXPERIMENTAL
Intervention: Omron HEM‐907 blood pressure measuring device
Number of subjects: 104
Study: 16146617

Group type: EXPERIMENTAL
Intervention: Doxycycline hyclate 20 mg bid
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Doxycycline hyclate 100 mg daily for eight weeks
Number of subjects: 12
Study: 12838196

Group type: EXPERIMENTAL
Intervention: Formula supplemented with DHA (0.36%) + ARA (0.72%)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Commercial formula
Number of subjects: 61
Study: 11006368

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (no growth hormone treatment)
Number of subjects: 38
Study: 8708225

Group type: EXPERIMENTAL
Intervention: Toothbrush
Number of subjects: 2

Group type: COMPARATOR
Intervention: Foam swabs
Number of subjects: 2
Study: 1360714

Group type: EXPERIMENTAL
Intervention: Chrisanolum (Chr)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Sulfasalicylic drugs (SSD)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Methotrexate (MT)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Nonsteroidal anti-inflammatory drugs (NSAID)
Number of subjects: 126
Study: 3901360

Group type: EXPERIMENTAL
Intervention: 200 milligrams of doxycycline preoperatively
Number of subjects: 51

Group type: COMPARATOR
Intervention: 5 grams of cefamandole in four doses over a period of 18 hours
Number of subjects: 51
Study: 31509204

Group type: EXPERIMENTAL
Intervention: Enhanced implementation approach (coaching, collaborative peer learning, and peer comparison feedback)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual implementation approach
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Quality improvement toolkit
Number of subjects: 20
Study: 29303840

Group type: EXPERIMENTAL
Intervention: Early palliative care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Palliative care interventions delivered by an interdisciplinary team
Number of subjects: 0
Study: 27518403

Group type: EXPERIMENTAL
Intervention: IFN-α2b spray
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 25218597

Group type: EXPERIMENTAL
Intervention: Medical Nutrition Therapy (MNT)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 76

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 76
Study: 22118328

Group type: EXPERIMENTAL
Intervention: Cardiac revascularization
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Cardiac revascularization (responders)
Number of subjects: 52
Study: 20177797

Group type: EXPERIMENTAL
Intervention: Women with breast cancer (group B, n = 18)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Women without breast cancer (group A, n = 17)
Number of subjects: 35
Study: 17917469

Group type: EXPERIMENTAL
Intervention: 5 psychotherapeutic sessions based on the modified reattribution model
Number of subjects: 91

Group type: COMPARATOR
Intervention: Psychoeducational reading material
Number of subjects: 91
Study: 15771333

Group type: EXPERIMENTAL
Intervention: Conventional medium-hard toothbrush 'Pingu'
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Conventional soft toothbrush 'CuraKid'
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Three-headed toothbrush 'Superbrush'
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 47
Study: 12742300

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 5000
Study: 10096928

Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg/d for 3 days, then 500 mg/wk for 3 months)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 302
Study: 9735596

Group type: EXPERIMENTAL
Intervention: Key size of 6 mm
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Key size of 12 mm
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Key size of 21 mm
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Key size of 30 mm
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Inter-key spacing of 3 mm
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Inter-key spacing of 0 mm
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Inter-key spacing of 3, 6, and 12 mm
Number of subjects: 9
Study: 1867419

Group type: EXPERIMENTAL
Intervention: Oral atropine (0.02 mg/kg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Oral glycopyrrolate (0.05 mg/kg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 90
Study: 6617931

Group type: EXPERIMENTAL
Intervention: 2 g of L-carnitine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 28604135

Group type: EXPERIMENTAL
Intervention: SOY+RT (25 g of soy protein with resistance training)
Number of subjects: 32

Group type: COMPARATOR
Intervention: PL+RT (25 g of maltodextrin placebo with resistance training)
Number of subjects: 32
Study: 27090817

Group type: EXPERIMENTAL
Intervention: Casein glycomacropeptide (CGMP) 30 g daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard treatment (4800 mg oral mesalamine daily)
Number of subjects: 24
Study: 25148789

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab 0.3 mg
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab 0.5 mg
Number of subjects: 759

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 759
Study: 22792813

Group type: EXPERIMENTAL
Intervention: Double fill nine tastes soup, water frying points 2 times orally, for 2 months
Number of subjects: 77

Group type: COMPARATOR
Intervention: Transfer factor oral liquid, 10 mL, 2 times daily orally, for 2 months
Number of subjects: 77
Study: 19725893

Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone 50/100 microg BD via Diskus
Number of subjects: 42

Group type: COMPARATOR
Intervention: Fluticasone 100 microg BD via Diskus
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study: 18670224

Group type: EXPERIMENTAL
Intervention: In utero exposure to maternal HAART
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zidovudine exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postnatal exposure to HAART
Number of subjects: 0
Study: 15702295

Group type: EXPERIMENTAL
Intervention: Photons (60 Gy, 30 fractions; 8 MV, (60)Co)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Neutrons (18 Gy, twelve fractions; 66 MeV(p‐‐>Be))
Number of subjects: 27
Study: 12957267

Group type: EXPERIMENTAL
Intervention: Vascular brachytherapy (VBT) with a (90)Sr/(90)Y source, prescribed dose at 2 mm from the centerline of the source axis was 18.4 Gy or 23 Gy
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Vascular brachytherapy (VBT) with a (90)Sr/(90)Y source
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 11106135

Group type: EXPERIMENTAL
Intervention: Sertraline-Continuation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo-Switch
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo-Responder
Number of subjects: 50
Study: 8852770

Group type: EXPERIMENTAL
Intervention: Barium‐Mucofalk
Number of subjects: 40

Group type: COMPARATOR
Intervention: Barium‐methylcellulose
Number of subjects: 40
Study: 1387767

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Ondansetron 16 mg
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 6329547

Group type: EXPERIMENTAL
Intervention: 5 mg enalapril twice daily (n = 18)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (n = 18)
Number of subjects: 36
Study: 31272495

Group type: COMPARATOR
Intervention: Standard of care with quarterly clinic visits
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Oral HIVST with biannual clinic visits plus oral HIVSTs
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Blood-based HIVST with biannual clinic visits plus blood-based HIVSTs
Number of subjects: 495
Study: 31252222

Group type: EXPERIMENTAL
Intervention: Biperiden (M1 receptor antagonist, 4 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 28552878

Group type: EXPERIMENTAL
Intervention: LD+MCT (L-leucine 1.2 g, cholecalciferol 20 μg, 6 g of MCT)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: LD+LCT (L-leucine 1.2 g, cholecalciferol 20 μg, 6 g of long-chain triglycerides)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (no supplements)
Number of subjects: 38
Study: 25905714

Group type: EXPERIMENTAL
Intervention: 45° elevated upper body position
Number of subjects: 55

Group type: COMPARATOR
Intervention: Nonelevated position
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 55
Study: 24330691

Group type: EXPERIMENTAL
Intervention: Sildenafil (phosphodiesterase 5 inhibitor) administered daily for a short term (duration not specified)
Number of subjects: 0
Study: 21554816

Group type: EXPERIMENTAL
Intervention: 10 g α-cyclodextrin
Number of subjects: 10
Study: 18277121

Group type: EXPERIMENTAL
Intervention: Rifampin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rifabutin
Number of subjects: 0
Study: 17137978

Group type: EXPERIMENTAL
Intervention: Aspherical IOL (Tecnis Z9000)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Spherical IOL (Sensar AR40e)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both IOLs
Number of subjects: 20
Study: 12626865

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intramuscular pethidine analgesia
Number of subjects: 100
Study: 11065083

Group type: EXPERIMENTAL
Intervention: BFHI training of medical, midwifery, and nursing staffs (experimental group)
Number of subjects: 17795

Group type: COMPARATOR
Intervention: Routine practices (control group)
Number of subjects: 17795
Study: 9056052

Group type: EXPERIMENTAL
Intervention: MK-462
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 16
Study: 8396099

Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg/day, single dose for three days)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Co-amoxiclav (tid for ten days, dosage according to manufacturer's instructions)
Number of subjects: 159
Study: 3002707

Group type: EXPERIMENTAL
Intervention: Omeprazole (60 mg daily for 7 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28857461

Group type: EXPERIMENTAL
Intervention: LY3127760
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 26948252

Group type: EXPERIMENTAL
Intervention: Intravenous frusemide and enteral indapamide (Group F + I)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous frusemide (Group F)
Number of subjects: 40
Study: 24499394

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural group therapy (CBT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Psychoeducation group programme (EDUC)
Number of subjects: 26
Study: 22357522

Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (WBV)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 10
Study: 20179318

Group type: EXPERIMENTAL
Intervention: Minorities perceived as expert
Number of subjects: 0

Group type: COMPARATOR
Intervention: Minorities not perceived as expert
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Majority members' deeper processing
Number of subjects: 0
Study: 17823938

Group type: EXPERIMENTAL
Intervention: Risk score based on 6 variables (age, heart rate, Glasgow Coma Scale score, cranial nerve palsies, cerebrospinal fluid leukocyte count < 1,000 cells/mm3, gram-positive cocci in cerebrospinal fluid Gram's stain)
Number of subjects: 696

Group type: COMPARATOR
Intervention: Risk score validation in the European Dexamethasone Study
Number of subjects: 696
Study: 15795549

Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 0
Study: 12848392

Group type: EXPERIMENTAL
Intervention: Bovine colostrum (60 g x day(-1))
Number of subjects: 51

Group type: COMPARATOR
Intervention: Whey protein powder
Number of subjects: 51
Study: 10594483

Group type: EXPERIMENTAL
Intervention: Fantofarone 100 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Fantofarone 300 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 8546738

Group type: EXPERIMENTAL
Intervention: cM‐T412 monoclonal antibody, 50 mg/day for 5 days, followed by 50 mg/week for 5 weeks (6 patients) or retreatment of 50 mg/day for 5 days after 5 weeks (6 patients)
Number of subjects: 12
Study: 1986287

Group type: EXPERIMENTAL
Intervention: 3 mg of cyclosporine per kilogram per day
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 5 mg of cyclosporine per kilogram per day
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 7.5 mg of cyclosporine per kilogram per day
Number of subjects: 85

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 85
Study: 7423283

Group type: EXPERIMENTAL
Intervention: PGE2 4.5 mg in the form of 0.5 mg oral tablets
Number of subjects: 22

Group type: COMPARATOR
Intervention: PGE2 4.5 mg in the form of tylose gel
Number of subjects: 22